Página principal > Resultados de la búsqueda: van de Kerkhof, P.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 6 registros encontrados en 0.02 segundos.
Artículos, Encontrados 6 registros
Artículos Encontrados 6 registros  
1.
7 p, 283.2 KB A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features : results from psoriasis patients in Spain / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Reich, Kristian (Sclderm Research Institute and Dermatologikum Hamburg) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot) ; Barker, J.N (King's College London) ; Girolomoni, G. (University of Verona) ; Paul, C. (Paul Sabatier University and Larrey Hospital) ; Universitat Autònoma de Barcelona
The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). [...]
2017 - 10.1111/jdv.14195
Journal of the European Academy of Dermatology and Venereology, Vol. 31 Núm. 7 (july 2017) , p. 1176-1182  
Registro completo - Creative Commons
2.
7 p, 769.8 KB An analysis of patient-reported outcomes in ixora-s : Comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Lomaga, Mark (DermEdge Research and Probity Medical Research) ; Hollister, Kristin (Eli Lilly and Company) ; Dutronc, Yves (Eli Lilly and Company) ; Berggren, Lovisa (HaaPACS GmbH) ; Van De Kerkhof, Peter C.M. (Radboud University Nijmegen Medical Centre) ; Universitat Autònoma de Barcelona
Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806). [...]
2020 - 10.2340/00015555-3700
Acta dermato-venereologica, Vol. 100 Núm. 19 (2020) , p. 1-7  
Registro completo - Creative Commons
3.
8 p, 509.9 KB Psoriasis and mental health workshop report : Exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk / Kleyn, C.Elise (Manchester Academic Health Science Centre) ; Talbot, Peter S. (University of Manchester) ; Mehta, Nehal N. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ; Sampogna, Francesca (IDI-IRCCS) ; Bundy, Chris (Cardiff University) ; Ashcroft, Darren M. (University of Manchester) ; Kimball, Alexa B. (Beth Israel Deaconess Medical Center) ; van de Kerkhof, Peter C.M. (International Psoriasis Council) ; Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ; Valenzuela, Fernando (University of Chile and Probity Medical Research) ; van der Walt, Joelle M. (International Psoriasis Council) ; Aberra, Tsion (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ; Puig-Verdié, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Psoriasis is a systemic, relapsing, inflammatory disease associated with serious comorbidities including mood problems and/or unhealthy lifestyle behaviours. Cutaneous and systemic abnormalities in innate and acquired immunity play a role in its pathogenesis. [...]
2020 - 10.2340/00015555-3375
Acta dermato-venereologica, Vol. 100 Núm. 1 (january 2020) , p. adv00020  
Registro completo - Creative Commons
4.
1 p, 118.3 KB Correction to : Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey / Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ; Langley, Richard G. (Dalhousie University) ; Paul, Carle (Paul Sabatier University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (University Medical Center Hamburg-Eppendorfi) ; van de Kerkhof, Peter (Radboud University Medical Center) ; Wu, Hsiuan-Lin (Amgen Inc) ; Richter, Sven (Amgen Inc) ; Jardon, Shauna (Amgen Inc) ; Gisondi, Paolo (University Hospital of Verona (Itàlia)) ; Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-021-00656-z
Dermatology and Therapy, Vol. 12 (january 2022) , p. 79  
Registro completo - Creative Commons
5.
16 p, 894.7 KB Evolution of Patient Perceptions of Psoriatic Disease : Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey / Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ; Langley, Richard G. (Dalhousie University) ; Paul, Carle (Paul Sabatier University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (University Medical Center Hamburg-Eppendorf) ; van de Kerkhof, Peter (Radboud University Medical Center) ; Wu, Hsiuan-Lin (Amgen Inc) ; Richter, Sven (Amgen Inc) ; Jardon, Shauna (Amgen Inc) ; Gisondi, Paolo (University Hospital of Verona (Itàlia)) ; Universitat Autònoma de Barcelona
Since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, several systemic treatments for psoriasis (PsO) and/or psoriatic arthritis (PsA) have been approved. The population-based UPLIFT survey was conducted to understand how perceptions of treatment-related outcomes have evolved, particularly for patients with mild to moderate PsO and/or PsA and their dermatologists. [...]
2021 - 10.1007/s13555-021-00635-4
Dermatology and Therapy, october 2021, p. 1-16  
Registro completo - Creative Commons
6.
9 p, 453.9 KB Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials / Strober, Bruce (Probity Medical Research) ; Gottlieb, Alice B (New York Medical College at Metropolitan Hospital) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot. Assistance Publique-Hôpitaux de Paris. Service de Dermatologie. Hôpital Saint-Louis) ; Chouela, E. (Universidad de Buenos Aires) ; Imafuku, S. (Department of Dermatology. Faculty of Medicine. Fukuoka University) ; Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Tan, H. (Pfizer Inc.) ; Valdez, H. (Pfizer Inc.) ; Gupta, P. (Pfizer Inc.) ; Kaur, M. (Pfizer Inc.) ; Frajzyngier, V. (Pfizer Inc.) ; Wolk, R. (Pfizer Inc.) ; Universitat Autònoma de Barcelona
Background: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. [...]
2019 - 10.1111/bjd.17149
British journal of dermatology, Vol. 180 Núm. 1 (january 2019) , p. 67-75  
Registro completo - Creative Commons

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos